ESTRO 2024 - Abstract Book

S630

Clinical - Breast

ESTRO 2024

63. Molina-Montes E, Perez-Nevot B, Pollan M, Sanchez-Cantalejo E, Espin J, Sanchez MJ. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast (Edinburgh, Scotland). 2014;23(6):721-42.

64. Veiga LH, Lubin JH, Anderson H, De Vathaire F, Tucker M, Bhatti P, et al. A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. Radiation research. 2012;178(4):365-76.

65. Haciislamoglu E, Canyilmaz E, Gedik S, Aynaci O, Serdar L, Yoney A. Effect of dose constraint on the thyroid gland during locoregional intensity ‐ modulated radiotherapy in breast cancer patients. Journal of Applied Clinical Medical Physics. 2019;20(7):135-41. 66. Bernstein JL, Haile RW, Stovall M, Boice JD, Shore RE, Langholz B, et al. Radiation Exposure, the ATM Gene, and Contralateral Breast Cancer in the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of the National Cancer Institute. 2010;102(7):475-83. 67. Okonogi N, Karasawa K, Nitta Y, Mori Y, Murata K, Wakatsuki M, et al. Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer. Breast cancer research and treatment. 2022;194(3):561-7.

68. Alves I, Marques JC. Radiation-induced angiosarcoma of the breast: a retrospective analysis of 15 years' experience at an oncology center. Radiol Bras. 2018;51(5):281-6.

69. Coco S, Boccardo S, Mora M, Fontana V, Vanni I, Genova C, et al. Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. Clinical breast cancer. 2021;21(3):218-30.e6.

70. Grantzau T, Thomsen MS, Vaeth M, Overgaard J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. Radiotherapy and Oncology. 2014;111(3):366-73.

71. Barry PN, Dragun AE. Risk of second primary lung cancer in women after radiotherapy for breast cancer. Breast Diseases. 2015;26(3):254-5.

72. Morton LM, Gilbert ES, Hall P, Andersson M, Joensuu H, Vaalavirta L, et al. Risk of treatment-related esophageal cancer among breast cancer survivors. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23(12):3081-91. 73. Journy N, Schonfeld SJ, Hauptmann M, Roberti S, Howell RM, Smith SA, et al. Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2020;151:33-9.

74. Kirova YM, Asselain B, Fourquet A. Can we consider always an esophageal carcinoma as radiation associated cancer after irradiation for breast cancer? American journal of clinical oncology. 2009;32(2):197-9.

75. Lai JH, Park G, Gerson LB. Association between breast cancer and the risk of colorectal cancer. Gastrointestinal Endoscopy. 2017;86(3):429-U214.

76. Haase D, Hanf V, Schulz T. [Therapy-related hematologic neoplasias after breast cancer. Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results]. Medizinische Klinik (Munich, Germany : 1983). 2004;99(9):506-17.